AXGT - Axovant Gene Therapies Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.57
-0.52 (-7.33%)
As of 12:57PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.09
Open7.09
Bid6.60 x 800
Ask6.61 x 800
Day's Range6.46 - 7.23
52 Week Range3.81 - 20.80
Volume334,162
Avg. Volume662,231
Market Cap149.669M
Beta (3Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire21 days ago

    Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the appointment of David Nassif as Chief Financial Officer, effective July 1, 2019. In addition, Axovant announced the expansion of its Board of Directors with the addition of Mr. Senthil Sundaram.

  • GlobeNewswire28 days ago

    Axovant Announces Poster Presentations at the 5th Congress of the European Academy of Neurology

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, announced two posters at the 5th Congress of the European Academy of Neurology (EAN) to be presented by Paul Korner, MD, SVP, Clinical Development and Medical Affairs.

  • GlobeNewswirelast month

    Axovant and Yposkesi Sign Strategic Gene Therapy Development and Manufacturing Partnership

    BASEL, Switzerland and CORBEIL-ESSONNES, France, June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announces it has signed a strategic partnership with Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production. Under this strategic collaboration, Yposkesi will provide expertise in process development, technology transfer, manufacturing scale-up, quality control and quality assurance.

  • GlobeNewswirelast month

    Axovant Announces Financial Results and Corporate Updates for Fourth Quarter and Fiscal Year Ended March 31, 2019

    Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and.

  • GlobeNewswire2 months ago

    Axovant Announces 6-Month Follow-Up Data From First Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD and Pipeline Update

    Axovant Gene Therapies, Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today reported six-month follow-up data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. AXO-Lenti-PD was observed to be generally well tolerated, with no serious adverse events related to the product or the procedure and patients showed continued improvement from baseline across multiple measurements. “Our patient-focused goal of improving motor function, reducing dyskinesia, lowering the requirement for oral levodopa, and improving quality of life is made possible by the continuous dopamine replacement strategy of AXO-Lenti-PD gene therapy.

  • GlobeNewswire2 months ago

    Axovant to Present at Upcoming Conferences in June

    BASEL, Switzerland, May 31, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.

  • GlobeNewswire2 months ago

    Axovant to Present at 2019 RBC Capital Markets Global Healthcare Conference

    BASEL, Switzerland, May 20, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.

  • NIH administers first clinical trial treatment for GM1 created by Auburn, UMass
    PR Newswire2 months ago

    NIH administers first clinical trial treatment for GM1 created by Auburn, UMass

    AUBURN, Ala., May 17, 2019 /PRNewswire/ -- The first clinical trial of a gene therapy treatment created through a research alliance between Auburn University and the University of Massachusetts has been administered in a child at the National Institutes of Health, or NIH, in Bethesda, Maryland. The NIH clinical trial is a significant milestone for GM1 gangliosidosis, a deadly disease with no approved treatment.

  • GlobeNewswire2 months ago

    Axovant Announces Dosing of First Patient in Clinical Program for AXO-AAV-GM1, a Novel Gene Therapy for GM1 Gangliosidosis

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced dosing of the first patient in a clinical study of AXO-AAV-GM1 (also known as AAV9-GLB1), an investigational gene therapy for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disorder caused by mutations in the GLB1 gene leading to impaired production of the beta-galactosidase enzyme.

  • GlobeNewswire2 months ago

    Axovant Announces Reverse Share Split Effectiveness

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that a reverse share split of its common shares on a 1-for-8 basis will become effective on May 7, 2019.  The shares will begin trading on the split-adjusted basis on the Nasdaq Global Select Market under the Company's existing trading symbol "AXGT" on May 8, 2019. The new CUSIP number following the reverse share split will be G0750W203. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019.

  • GlobeNewswire3 months ago

    Axovant Announces Dosing of First Patient in Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, announced the dosing of the first patient of the second cohort in the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD in Parkinson’s disease patients. “We are pleased to begin enrolling additional patients in the SUNRISE-PD study at a higher dose level, following encouraging 3-month data from the first cohort,” said Dr. Gavin Corcoran, Axovant’s Chief Research and Development Officer. “We look forward to exploring the full clinical potential of AXO-Lenti-PD in patients with Parkinson’s disease, building upon the safety profile and improvements in motor symptoms that have been observed in 17 patients evaluated across the ProSavin and AXO-Lenti-PD programs.

  • GlobeNewswire3 months ago

    Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

    -Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to.

  • GlobeNewswire4 months ago

    Axovant Announces Plan to Effect Reverse Share Split

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that its Board of Directors and a majority of its shareholders have approved a reduction of issued and outstanding common shares on a 1-for-8 basis that is expected to become effective in May 2019. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019. The Company also noted the closing of the public offering of common shares in March 2019 for gross proceeds of $40 million with participation from leading institutional shareholders.

  • GlobeNewswire4 months ago

    Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced additional data and plans for the AXO-AAV-GM2 and AXO-Lenti-PD programs, which will be highlighted at the Company’s R&D day for investors and analysts.

  • ACCESSWIRE4 months ago

    Axovant Sciences Gene Therapy Showing Progress, Pipeline Review

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • GlobeNewswire4 months ago

    Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

    Axovant Sciences (AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its common shares at a price to the public of $1.50 per share. Gross proceeds to Axovant from the offering are expected to be approximately $40,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,000,000 of its common shares on the same terms and conditions.  The offering is expected to close on March 18, 2019, subject to customary closing conditions.

  • GlobeNewswire4 months ago

    Axovant Sciences Announces Public Offering of Common Shares

    Axovant Sciences (AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase additional common shares in the offering on the same terms and conditions.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Making Moves on Monday

    CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.

  • GlobeNewswire4 months ago

    Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy

    Axovant (AXGT), a clinical-stage company developing innovative gene therapies, today reported three-month data from an investigator-initiated study administering investigational AXO-AAV-GM2 gene therapy in a patient with advanced infantile Tay-Sachs disease, a rare and fatal pediatric neurodegenerative genetic disorder characterized by impaired β-Hexosaminidase A enzyme production. AXO-AAV-GM2 is an investigational gene therapy designed to restore β-Hexosaminidase A enzyme activity in the central nervous system.

  • GlobeNewswire4 months ago

    Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease

    Axovant (AXGT), a clinical-stage company developing innovative gene therapies, today reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. The cohort consisted of two patients with advanced Parkinson’s disease who received a one-time administration of the lowest dose of AXO-Lenti-PD (4.2x106 TU). “Our focus in this first cohort of the SUNRISE-PD study was on the safety and tolerability of AXO-Lenti-PD, as well as the evaluation of efficacy using well-validated, objective measures.

  • GlobeNewswire5 months ago

    Axovant to Present at Cowen and Company 39th Annual Health Care Conference

    NEW YORK and BASEL, Switzerland, March 04, 2019 -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.

  • GlobeNewswire5 months ago

    Axovant to Host First R&D Day March 29, 2019

    NEW YORK and BASEL, Switzerland, Feb. 21, 2019 -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will.

  • GlobeNewswire5 months ago

    Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference

    NEW YORK and BASEL, Switzerland, Feb. 19, 2019 -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.